DBV Technologies (NASDAQ:DBVT) Share Price Passes Above 50-Day Moving Average - Time to Sell?

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) shares passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $8.63 and traded as high as $8.76. DBV Technologies shares last traded at $8.55, with a volume of 32,186 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on DBVT shares. Citigroup reiterated an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. The Goldman Sachs Group upgraded shares of DBV Technologies to a "sell" rating and set a $7.25 target price on the stock in a research note on Thursday, May 29th. JMP Securities increased their price target on shares of DBV Technologies from $15.00 to $21.00 and gave the company a "market outperform" rating in a report on Tuesday, May 27th. HC Wainwright boosted their price objective on shares of DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a report on Monday, May 5th. Finally, Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $14.75.

DBV Technologies Stock Performance

The business's fifty day moving average price is $8.67 and its 200-day moving average price is $5.63. The stock has a market cap of $234.18 million, a PE ratio of -1.90 and a beta of -0.66.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. The company had revenue of $0.51 million during the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. Analysts forecast that DBV Technologies S.A. will post -7.05 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.